What’s the current market cap for Dianthus Therapeutics, Inc. stock?

Dianthus Therapeutics, Inc. (DNTH) has a market cap of $4.5bn as of June 19, 2026.

What is the P/E ratio for Dianthus Therapeutics, Inc. stock?

The price to earnings (P/E) ratio for Dianthus Therapeutics, Inc. (DNTH) stock is 0 as of June 19, 2026.

Does Dianthus Therapeutics, Inc. stock pay dividends?

No, Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders as of June 19, 2026.

When is the next Dianthus Therapeutics, Inc. dividend payment date?

Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Dianthus Therapeutics, Inc.?

Dianthus Therapeutics, Inc. (DNTH) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Dianthus Therapeutics, Inc. stock | $DNTH Share Price

13:30

15:10

16:45

18:25

20:00

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Ticker

$DNTH

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

New York, United States

Website

dianthustx.com

DNTH Metrics

BasicAdvanced

$4.5bn

-$4.17

0.09

Bulls say / Bears say

Held approximately $1.2 billion in cash, cash equivalents and short-term investments as of March 31, 2026, providing financial runway into 2030.

Achieved an early GO decision in Part A of the Phase 3 CAPTIVATE trial for claseprubart in CIDP after 20 confirmed responders in under 40 participants, underscoring strong interim efficacy and safety.

Claseprubart was granted Orphan Drug Designation by the FDA for generalized Myasthenia Gravis, securing tax credits, fee waivers and potential seven-year market exclusivity upon approval.

Q1 2026 net loss widened to $40.8 million from $29.5 million a year earlier, driven by higher R&D and G&A spending, indicating accelerating cash burn.

Raised approximately $719 million in gross proceeds from an underwritten public offering in March 2026, substantially diluting existing shareholders and highlighting reliance on equity markets for funding.

Pivotal Phase 3 trial in generalized Myasthenia Gravis is on track to initiate in mid-2026 with top-line results not expected until 2H 2028, delaying a major commercialization catalyst.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Held approximately $1.2 billion in cash, cash equivalents and short-term investments as of March 31, 2026, providing financial runway into 2030.

Claseprubart was granted Orphan Drug Designation by the FDA for generalized Myasthenia Gravis, securing tax credits, fee waivers and potential seven-year market exclusivity upon approval.

Q1 2026 net loss widened to $40.8 million from $29.5 million a year earlier, driven by higher R&D and G&A spending, indicating accelerating cash burn.

Pivotal Phase 3 trial in generalized Myasthenia Gravis is on track to initiate in mid-2026 with top-line results not expected until 2H 2028, delaying a major commercialization catalyst.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

About Dianthus Therapeutics, Inc.

Ticker

Employees

DNTH Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

DNTH News

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Buy $DNTH

Lightyear

Legal

Work with us

Bulls say / Bears say

Dianthus Therapeutics, Inc./$DNTH

About Dianthus Therapeutics, Inc.

Ticker

Employees

DNTH Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

DNTH News

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

What’s the current market cap for Dianthus Therapeutics, Inc. stock?

What is the P/E ratio for Dianthus Therapeutics, Inc. stock?

Does Dianthus Therapeutics, Inc. stock pay dividends?

When is the next Dianthus Therapeutics, Inc. dividend payment date?

What is the beta indicator for Dianthus Therapeutics, Inc.?

Bulls say / Bears say